You have free access to this content

Cancer

Cover image for Cancer

15 December 2000

Volume 89, Issue 12

Pages 2515–2686

  1. Original Article

    1. Top of page
    2. Original Article
    1. Disease Site

      Blood/Bone Marrow
      You have free access to this content
      Superior vena cava syndrome secondary to an angiotropic large cell lymphoma : A case report (pages 2515–2520)

      Diane M. F. Savarese, Michael Zavarin, Mark S. Smyczynski, Michael J. Rohrer and Michael J. Hutzler

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2515::AID-CNCR1>3.0.CO;2-H

      • original image
      • original image

      A case of angiotropic large cell lymphoma presenting in large blood vessels as superior vena cava syndrome is presented. The discussion focuses on aspects of a particular predilection for the intravascular space in this unusual presentation.

    2. Breast Disease
      You have free access to this content
      Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma : Results of a randomized controlled trial (pages 2521–2526)

      Soo-Mee Bang, Dae Seog Heo, Ki Hyeong Lee, Jae Ho Byun, Heung Moon Chang, Dong-Yong Noh, Kuk Jin Choe, Yung-Jue Bang, Sung Rok Kim and Noe Kyeong Kim

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2521::AID-CNCR2>3.0.CO;2-F

      • original image
      • original image

      In this randomized controlled trial, adjuvant doxorubicin and cyclophosphamide chemotherapy showed no survival benefit compared with conventional cyclophosphamide, methotrexate, and 5-fluorouracil in premenopausal women with axillary lymph node positive breast carcinoma.

    3. You have free access to this content
      Computer simulations of lymph node metastasis for optimizing the pathologic examination of sentinel lymph nodes in patients with breast carcinoma (pages 2527–2537)

      Gelareh Farshid, Malcolm Pradhan, James Kollias and P. Grantley Gill

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2527::AID-CNCR3>3.0.CO;2-6

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The detection of lymph node metastases is highly dependent on the sampling methods used to look for them. A computer model of a sentinel lymph node is used to compare the efficacy and cost of various pathologic sampling strategies.

    4. You have free access to this content
      Imaging–histologic discordance at percutaneous breast biopsy : An indicator of missed cancer (pages 2538–2546)

      Laura Liberman, Michele Drotman, Elizabeth A. Morris, Linda R. LaTrenta, Andrea F. Abramson, Maureen F. Zakowski and D. David Dershaw

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2538::AID-CNCR4>3.0.CO;2-#

      • original image
      • original image
      • original image

      Discordance between histologic and imaging findings occurred in 3.1% of lesions that had percutaneous breast biopsy. Imaging–histologic discordance was shown to be an indication for surgical excision because of the high (24.4%) prevalence of carcinoma in these lesions.

    5. Endocrine Disorders
      You have free access to this content
      Delayed 18F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas (pages 2547–2554)

      Yuji Nakamoto, Tatsuya Higashi, Harumi Sakahara, Nagara Tamaki, Masafumi Kogire, Ryuichiro Doi, Ryo Hosotani, Masayuki Imamura and Junji Konishi

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2547::AID-CNCR5>3.0.CO;2-V

      • original image
      • original image
      • original image

      Delayed 18F-fluoro-2-deoxy-D-glucose positron emission tomography scanning at 2 hours postinjection may contribute to differentiation between malignant lesions and benign lesions in the pancreas.

    6. Gastrointestinal Tract
      You have free access to this content
      Early carcinoma of the gastric cardia in Japan : Is it different from that in the West? (pages 2555–2559)

      Takehiro Okabayashi, Takuji Gotoda, Hitoshi Kondo, Tetsuya Inui, Hiroyuki Ono, Daizo Saito, Shigeaki Yoshida, Mitsuru Sasako and Tadakazu Shimoda

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2555::AID-CNCR6>3.0.CO;2-R

      There are many significant differences in the clinicopathologic characteristics between patients with carcinoma of the gastric cardia and those with distal gastric carcinoma in Japan. Obesity, smoking, drinking, Barrett esophagus, or gastroesophageal reflux disease were not related to its occurrence, in contrast to reports in the West.

    7. You have free access to this content
      Circulating soluble Fas ligand in patients with gastric carcinoma (pages 2560–2564)

      Souichi Tsutsumi, Hiroyuki Kuwano, Tatsuo Shimura, Nobuhiro Morinaga, Erito Mochiki and Takayuki Asao

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2560::AID-CNCR7>3.0.CO;2-Q

      • original image
      • original image

      Patients with gastric carcinoma with high levels of soluble Fas ligand (sFasL) had a worse prognosis than those with low levels. The serum sFasL levels could be a prognostic tumor marker for the assessment of the progression of advanced gastric carcinoma.

    8. Genitourinary Tract
      You have free access to this content
      Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy (pages 2565–2569)

      Penny R. Anderson, Alexandra L. Hanlon, Eric Horwitz, Wayne Pinover and Gerald E. Hanks

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2565::AID-CNCR8>3.0.CO;2-I

      • original image
      • original image
      • original image
      • original image

      This is the first radiation therapy series to specifically and solely analyze outcome of prostate cancer patients with Gleason score 7. This report demonstrates the importance of higher central axis doses (≥ 76 Gy) in treating these patients with definitive three-dimensional conformal radiation therapy.

    9. You have free access to this content
      Low doses of oral dexamethasone for hormone-refractory prostate carcinoma (pages 2570–2576)

      Kazuo Nishimura, Norio Nonomura, Yutaka Yasunaga, Natsuki Takaha, Hitoshi Inoue, Hideki Sugao, Seiji Yamaguchi, Osanu Ukimura, Tsuneharu Miki and Akihiko Okuyama

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2570::AID-CNCR9>3.0.CO;2-H

      • original image

      Low doses of dexamethasone improved anemia, osseous disease, and the serum prostate specific antigen level in patients with hormone-refractory prostate carcinoma. A posttherapy PSA decline of ≥ 50% was found to be associated significantly with improved survival.

    10. You have free access to this content
      Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy (pages 2577–2586)

      Steven R. Potter, Leslie A. Mangold, Matthew J. Shue, David C. Taylor, Kristen L. Lecksell, Jonathan I. Epstein, Patrick C. Walsh and Alan W. Partin

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2577::AID-CNCR10>3.0.CO;2-V

      • original image
      • original image
      • original image

      Immunohistochemical and molecular methods were used to examine archival lymph nodes (LNs) removed from 102 men who had undergone radical prostatectomy for clinically localized prostate carcinoma and whose tumors had seminal vesicle invasion and negative pelvic LNs at surgery. Careful histologic, immunohistochemical, and molecular LN reevaluation identified prostate carcinoma metastases in only 9 (8.8%) men originally classified as free of lymphatic metastases.

    11. Head and Neck Disease
      You have free access to this content
      Induction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of head and neck : A Phase II trial (pages 2587–2596)

      John C. Grecula, Roy E. Smith, Chris A. Rhoades, Pramod Sharma, Amit Agrawal, Hong Zhang, James Allen, Federico P. Goldman, Donn Young and David E. Schuller

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2587::AID-CNCR11>3.0.CO;2-R

      • original image

      Induction paclitaxel (250 mg/m2, 24-hour infusion, every 21 days) for 3 courses produces a 50% objective response rate (10% complete response; 40% partial response) in patients with previously untreated resectable advanced squamous cell carcinomas of the head and neck.

    12. You have free access to this content
      Increased expression of c-erbB-3 protein and proliferating cell nuclear antigen during development of verrucous carcinoma of the oral mucosa (pages 2597–2605)

      Kazunari Sakurai, Masahiro Urade, Yumiko Takahashi, Hiromitsu Kishimoto, Kazuma Noguchi, Hitoshi Yasoshima and Akira Kubota

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2597::AID-CNCR12>3.0.CO;2-N

      • original image
      • original image
      • original image
      • original image

      Study results suggested that c-erbB-3 expression was an index of malignancy during the progression from verrucous premalignant lesions to malignant lesions of the oral mucosa and that it might have been involved in patient outcome.

    13. Hepatobiliary Tract
      You have free access to this content
      The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma (pages 2606–2612)

      Zhijian Zhang, Qi Liu, Jia He, Jiamei Yang, Guangshun Yang and Mengchao Wu

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2606::AID-CNCR13>3.0.CO;2-T

      • original image
      • original image

      Preoperative transcatheter arterial chemoembolization (TACE) effectively improved disease-free survival after hepatectomy for both resectable and small hepatocellular carcinoma. Depending upon tumor size, range, hepatic function, and TACE effect, TACE was performed 2–4 times for 6 months before surgery.

    14. Lung Disease
      You have free access to this content
      Histopathologic findings of lung carcinoma in German uranium miners (pages 2613–2621)

      Michaela Kreuzer, Klaus M. Müller, Annemarie Brachner, Michael Gerken, Bernd Grosche, Thorsten Wiethege and H.-Erich Wichmann

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2613::AID-CNCR14>3.0.CO;2-Y

      In a group of 240 uranium miners whose lung carcinoma was diagnosed between 1991 and 1995, small cell lung carcinoma and squamous cell carcinoma appeared more, and adenocarcinoma was less likely to be radiation-induced, particularly among ex- and never-smokers.

    15. You have free access to this content
      Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma : A Phase II study (pages 2622–2629)

      Javier Rodriguez, Javier Cortes, Emiliano Calvo, Ignacio Azinovic, Oscar Fernandez-Hildago, Rafael Martinez-Monge, Carlos Garzon, Jokin de Irala, Maite Martinez-Aguillo, Teresa Ramon y Cajal and Antonio Brugarolas

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2622::AID-CNCR15>3.0.CO;2-X

      • original image

      Paclitaxel, cisplatin, and gemcitabine combination chemotherapy is feasible and highly active in the treatment of metastatic nonsmall cell lung carcinoma.

    16. Skin and Soft Tissue
      You have free access to this content
      Cisplatin, dacarbazine, and fotemustine plus interferon α in patients with advanced malignant melanoma : A multicenter Phase II study of the Southern Italy Cooperative Oncology Group (pages 2630–2636)

      Antonio Daponte, Paolo A. Ascierto, Adriano Gravina, Maria Teresa Melucci, Giuseppe Palmieri, Pasquale Comella, Riccardo Cellerino, Mario DeLena, Giovanni Marini and Giuseppe Comella

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2630::AID-CNCR16>3.0.CO;2-Z

      • original image

      Sixty-four consecutive patients with advanced melanoma were treated with a combination of fotemustine 100 mg/m2 intravenously (i.v.) on Day 1, dacarbazine 300 mg/m2 i.v. on Days 2–4, and cisplatin 25 mg/m2 i.v. on Days 3 and 4 recycled every 3–4 weeks. Interferon α2b was administered at a dose of 3 MIU intramuscularly three times per week until disease progression. This treatment schedule demonstrated significant activity by increasing both the proportion of patients who achieved a complete response and the probability of long term survival in patients with advanced, untreated melanoma.

    17. Discipline

      Translational Research
      You have free access to this content
      COX-2 is expressed in human pulmonary, colonic, and mammary tumors (pages 2637–2645)

      Robert A. Soslow, Andrew J. Dannenberg, Demaretta Rush, B. M. Woerner, K. Nasir Khan, J. Masferrer and Alane T. Koki

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B

      • original image
      • original image
      • original image
      • original image
      • original image

      The inducible form of the cyclooxygenase (COX) enzyme, COX-2, has been shown to be important in carcinogenesis. In this study, immunohistochemistry was used to document significant overexpression of COX-2 in common human cancers and their precursors. Collectively, these data suggest that COX-2 inhibitors may be utilized to prevent and treat neoplasms of the lung, colon, and breast.

    18. You have free access to this content
      Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer (pages 2646–2654)

      Pierre L. Triozzi, Reema Khurram, Wayne A. Aldrich, Michael J. Walker, Julian A. Kim and Sean Jaynes

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2646::AID-CNCR18>3.0.CO;2-A

      • original image
      • original image
      • original image
      • original image

      Dendritic cells derived in vitro can exist viably after intratumoral injection and can mediate biologic activity in situ in patients with metastatic breast carcinoma and melanoma.

    19. Medical Oncology
      You have free access to this content
      Carcinoma of unknown primary site : Long term follow-up after treatment with paclitaxel, carboplatin, and etoposide (pages 2655–2660)

      F. Anthony Greco, Howard A. Burris III, Joan B. Erland, James R. Gray, Leonard A. Kalman, Marshall T. Schreeder and John D. Hainsworth

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2655::AID-CNCR19>3.0.CO;2-9

      • original image

      Treatment with paclitaxel, carboplatin, and etoposide produced a 48% response rate and 1-year, 2-year, and 3-year survival rates of 48%, 20%, and 14%, respectively, in patients who had unknown primary site carcinomas.

    20. You have free access to this content
      All-trans retinoic acid and interferon-α in the treatment of a patient with resistant metastatic osteosarcoma : A case report (pages 2661–2666)

      Alessandra Todesco, Modesto Carli, Isabella Iacona, Emanuela Frascella, Vito Ninfo and Angelo Rosolen

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2661::AID-CNCR20>3.0.CO;2-9

      • original image
      • original image

      A 14-year-old boy diagnosed with recurrent osteosarcoma that was resistant to chemotherapy was treated with all-trans retinoic acid and interferon-α. The response obtained and the low toxicity observed suggest that such a therapy could be useful in selected patients with recurrent osteosarcoma and might be effective in the treatment of minimal residual disease.

    21. Epidemiology
      You have free access to this content
      Different age limits for elderly patients with indolent and aggressive non-Hodgkin lymphoma and the role of relative survival with increasing age : Analysis of a population-based non-Hodgkin lymphoma registry (pages 2667–2676)

      Eduard Maartense, Hanneke C. Kluin-Nelemans, Saskia le Cessie, Philip M. Kluin, Simone Snijder and Evert M. Noordijk

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2667::AID-CNCR21>3.0.CO;2-P

      • original image
      • original image

      Analysis of a population-based registry with non-Hodgkin lymphoma patients, using cohorts of different age groups, shows that the definition by which age patients should be considered “elderly” depends on histologic type according to the revised European-American lymphoma classification and on the age-adjusted International Prognostic Index (IPI) score. Patients with indolent NHL become “elderly” when they are 70 years old, and patients with aggressive NHL when they are 65 years old, whereas for patients with an IPI score nil, age older than 75 years becomes the dominant prognostic factor. The decrease in relative survival rate diminished for patients older than 70 years.

    22. Pathology
      You have free access to this content
      The percutaneous needle biopsy is safe and recommended in the diagnosis of musculoskeletal masses : Outcomes analysis of 155 patients at a sarcoma referral center (pages 2677–2686)

      James A. Welker, Robert M. Henshaw, James Jelinek, Barry M. Shmookler and Martin M. Malawer

      Version of Record online: 20 DEC 2000 | DOI: 10.1002/1097-0142(20001215)89:12<2677::AID-CNCR22>3.0.CO;2-L

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      When a patient suspected of having a sarcoma initially undergoes a needle biopsy, an open biopsy can be avoided 90% of the time, and the outcomes are equally as good as with the open biopsy method.

SEARCH

SEARCH BY CITATION